Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 8:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 341 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Anti-Inflammatory Agents Clear all
Completed Phase 2 Interventional Results available

Anti-INFLammatory to Address Mood and Endothelial Dysfunction (INFLAMED)

NCT01625845
View directory record Official record
Conditions
Major Depressive Disorder, Depression, Depressive Symptoms, Cardiovascular Disease (CVD), Coronary Artery Disease (CAD), Heart Disease
Interventions
Pentoxifylline, Placebo, Standard Treatment
Drug · Other · Behavioral
Lead sponsor
Indiana University
Other
Eligibility
40 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Oct 22, 2026, 8:44 AM EDT
Terminated Phase 2 Interventional Results available

COlchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19

NCT04363437
View directory record Official record
Conditions
Coronavirus Infection
Interventions
Colchicine, Usual Care
Drug
Lead sponsor
Maimonides Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Feb 18, 2022 · Synced Oct 22, 2026, 8:44 AM EDT
Completed Phase 2 Interventional Results available

Early Treatment for Acute ACL Tear

NCT01692756
View directory record Official record
Conditions
Anterior Cruciate Ligament (ACL) Tears
Interventions
Kenalog or placebo, Kenalog then Placebo, Kenalog, Placebo
Drug
Lead sponsor
Cale Jacobs
Other
Eligibility
14 Years to 33 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Oct 22, 2026, 8:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Non-steroidal Anti-inflammatory Drugs (NSAIDS) on Acclimatization to High Altitude

NCT02233582
View directory record Official record
Conditions
High Altitude
Interventions
Ibuprofen, Sugar pill
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
Bishop, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2021 · Synced Oct 22, 2026, 8:44 AM EDT
Completed Phase 1 Interventional

A Phase I Study of Methotrexate for HIV Infection

NCT00000834
View directory record Official record
Conditions
HIV Infections
Interventions
Lamivudine, Methotrexate, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
7
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Wichita, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 22, 2026, 8:44 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes.

NCT04840199
View directory record Official record
Conditions
HIV Infections, Cytomegalovirus, CMV
Interventions
Letermovir Oral Tablet
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
40 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
15
States / cities
San Diego, California • San Francisco, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Oct 22, 2026, 8:44 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Variability in Response to Non-steroidal Anti-inflammatory Drugs

NCT02502006
View directory record Official record
Conditions
Healthy
Interventions
Celecoxib, Naproxen, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Oct 22, 2026, 8:44 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis

NCT00819195
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Glatiramer acetate
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2013 · Synced Oct 22, 2026, 8:44 AM EDT
Completed No phase listed Observational

Hashimotos Thyroiditis and Thyroid Cancer

NCT01428167
View directory record Official record
Conditions
Thyroid Cancer, Hashimotos Thyroiditis
Interventions
Not listed
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Oct 22, 2026, 8:44 AM EDT
Completed Not applicable Interventional Results available

Using the Cholinergic Anti-Inflammatory Pathway to Treat Systemic Lupus Musculoskeletal Pain

NCT02822989
View directory record Official record
Conditions
Lupus Erythematosus, Systemic, Musculoskeletal Pain
Interventions
Vagus nerve stimulation, Sham vagus nerve stimulation
Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 22, 2026, 8:44 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Sulforaphane in Broccoli Sprouts on Nrf2 Activation

NCT01315665
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Broccoli sprouts
Dietary Supplement
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 49 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 22, 2026, 8:44 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Examination of the Anti-inflammatory and Insulin Sensitizing Properties of Doxycycline in Humans

NCT01375491
View directory record Official record
Conditions
Type 2 Diabetes, Obesity
Interventions
Doxycycline, Placebo
Drug · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 60 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 22, 2026, 8:44 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

NSAID vs. Narcotics

NCT02915055
View directory record Official record
Conditions
Multimodal Analgesia, Nonsteroidal Anti-inflammatory Drugs
Interventions
Ibuprofen 600 mg, standard oxycodone/acetaminophen
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Oct 22, 2026, 8:44 AM EDT
Completed Phase 4 Interventional Results available

Pharmacokinetics & Safety of Diclofenac Potassium Oral Solution in Ped. Subjects (2-12 Yrs) With Mild-Mod. Acute Pain

NCT02287350
View directory record Official record
Conditions
Pain
Interventions
diclofenac potassium oral solution
Drug
Lead sponsor
Depomed
Industry
Eligibility
2 Years to 12 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
5
States / cities
Sheffield, Alabama • Stanford, California • City of Saint Peters, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 22, 2026, 8:44 AM EDT
Withdrawn Phase 2 Interventional

Preventing Frequent Sinus Infections in HIV-Infected Patients

NCT00000752
View directory record Official record
Conditions
HIV Infections, Sinusitis
Interventions
Pseudoephedrine hydrochloride, Guaifenesin, Cefuroxime axetil, Beclomethasone dipropionate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1993
U.S. locations
10
States / cities
San Diego, California • San Francisco, California • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 22, 2026, 8:44 AM EDT
Completed Phase 4 Interventional

Oral Aspirin + Ketamine as Adjunct to Oral Antidepressant Therapy for Depression

NCT05615948
View directory record Official record
Conditions
Treatment Resistant Depression, Major Depressive Disorder, Analgesia, Ketamine, Peripheral Nervous System Agents, Central Nervous System Depressants, Neurotransmitter Agents, Anti-Inflammatory Agents, Physiological Effects of Drugs, Sensory System Agents, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Non-Steroidal, Depressive Symptoms
Interventions
VTS-K
Drug
Lead sponsor
Theresa Jacob, PhD, MPH
Other
Eligibility
18 Years to 89 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 22, 2026, 8:44 AM EDT
Completed Phase 2Phase 3 Interventional

A Multicenter Trial of Rofecoxib and Naproxen in Alzheimer's Disease (NSAID Study)

NCT00004845
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Rofecoxib, Naproxen
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
55 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
40
States / cities
Phoenix, Arizona • Tucson, Arizona • Irvine, California + 34 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2009 · Synced Oct 22, 2026, 8:44 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of a Neuroprotective Drug to Limit the Extent of Damage From an Ischemic Stroke

NCT00630396
View directory record Official record
Conditions
Stroke, Acute
Interventions
Minocycline
Drug
Lead sponsor
David Hess, MD
Other
Eligibility
19 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Lexington, Kentucky • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 13, 2012 · Synced Oct 22, 2026, 8:44 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Sustained Acoustic Medicine (SAM) for Symptomatic Treatment of Pain Related to Bone Fracture

NCT05883241
View directory record Official record
Conditions
Bone Fracture, Fresh Fracture
Interventions
Sustained Acoustic Device with 2.5% Diclofenac Patch, 2.5% Diclofenac Patches
Device · Drug
Lead sponsor
ZetrOZ, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
2
States / cities
Trumbull, Connecticut • Lansdowne, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 22, 2026, 8:44 AM EDT
Completed Phase 2 Interventional Results available

Meloxicam vs Placebo for Mobilization

NCT02003625
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Multiple Myeloma, Hematopoietic Stem Cells
Interventions
GCSF, meloxicam, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 18, 2020 · Synced Oct 22, 2026, 8:44 AM EDT
Completed Phase 3 Interventional Results available

Effect Of Pregabalin Treatment In Patients With Diabetic Nerve Pain Who Currently Use A Non-Steroid Anti-Inflammatory Drug (NSAID) For Another Pain

NCT01455415
View directory record Official record
Conditions
Painful Diabetic Peripheral Neuropathy
Interventions
pregabalin, placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
55
States / cities
Goodyear, Arizona • Phoenix, Arizona • Tucson, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 22, 2026, 8:44 AM EDT
Completed Phase 3 Interventional

Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation

NCT04368559
View directory record Official record
Conditions
Candidemia, Mycoses, Fungal Infection, Fungemia, Invasive Candidiasis, Pneumocystis, Mold Infection, Invasive Fungal Disease, Prophylaxis of Invasive Fungal Infections, Aspergillus
Interventions
Rezafungin for Injection, Posaconazole, Fluconazole, Trimethoprim-sulfamethoxazole (TMP/SMX), Intravenous Placebo, Oral Placebo
Drug
Lead sponsor
Mundipharma Research Limited
Industry
Eligibility
18 Years and older
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 22, 2026, 8:44 AM EDT
Completed Phase 3 Interventional

Anti-Inflammatory Treatment for Age-Associated Memory Impairment: A Double-Blind Placebo-Controlled Trial

NCT00009230
View directory record Official record
Conditions
Memory Disorders
Interventions
Celecoxib
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
40 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 22, 2026, 8:44 AM EDT
Not listed Phase 2Phase 3 Interventional

The Influence Of a Natural Anti-Inflammatory Product On Levels Of Inflammatory Markers In Cases With Osteoarthritis Of Knee

NCT02333084
View directory record Official record
Conditions
Osteoarthritis
Interventions
PRN Joint Health Formula, placebo, PRN Flex Omega Benefits® combination
Dietary Supplement
Lead sponsor
Physician Recommended Nutriceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 4, 2016 · Synced Oct 22, 2026, 8:44 AM EDT